Antibiotic Susceptibility Monitoring of Neisseria gonorrhoeae in Bacolod City, Philippines
Abstract
:1. Introduction
2. Materials and Methods
2.1. Inclusion and Exclusion Criteria
2.2. Bacterial Isolation and Identification
2.3. Antibiotic Susceptibility Testing
2.4. Beta-Lactamase Production
2.5. Quality Control
2.6. Data Analysis
2.7. Ethical Consideration
2.8. Results
3. Discussion
4. Conclusions
Supplementary Materials
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Crowley, L. Communicable Diseases in an Introduction to Human Disease: Pathology and Pathophysiology Correlations, 7th ed.; Jones and Bartlett: Burlington, MA, USA, 2007; pp. 154–157. [Google Scholar]
- Hammerschlag, M.; Sleiman, J. Conjunctivitis in the Neonate in Pediatric Practice Infectious Disease; Shah, S., Ed.; McGraw Hill: New York, NY, USA, 2009; pp. 175–177. [Google Scholar]
- Unemo, M.; del Rio, C.; Shafer, W. Antimicrobial resistance expressed by Neisseria gonorrhoeae: A major global public health problem in the 21st century. Microbiol. Spectr. 2016, 4. [Google Scholar] [CrossRef]
- Ndowa, F.; Lusti-Narasimhan, M. The threat of untreatable gonorrhoea: Implications and consequences for reproductive and sexual morbidity. Reprod. Health Matters 2012, 20, 76–82. [Google Scholar] [CrossRef]
- Allen, V.; Mitterni, L.; Seah, C.; Rebbapragada, A.; Martin, I.; Lee, C.; Siebert, H.; Towns, L.; Melano, R.; Low, D. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013, 309, 163–170. [Google Scholar] [CrossRef] [PubMed]
- Lahra, M.; Enriquez, R. Australian gonococcal surveillance programme, 1 April to 30 June 2016. Commun. Dis. Intell. Q. Rep. 2016, 40, E557–E559. [Google Scholar] [PubMed]
- Wind, C.M.; Schim van der Loeff, M.F.; van Dam, A.P.; de Vries, H.J.; van der Helm, J.J. Trends in antimicrobial susceptibility for azithromycin and ceftriaxone in Neisseria gonorrhoeae isolates in Amsterdam, the Netherlands, between 2012 to 2015. Eurosurveillance 2017, 22. [Google Scholar] [CrossRef] [PubMed]
- Gong, Z.; Lai, W.; Liu, M.; Hua, Z.; Sun, Y.; Xu, Q.; Xia, Y.; Zhao, Y.; Xie, X. Novel genes related to ceftriaxone resistance found among ceftriaxone-resistant Neisseria gonorrhoeae strains selected in vitro. Antimicrob. Agents Chemother. 2016, 60, 2043–2051. [Google Scholar] [CrossRef] [PubMed]
- Regnath, T.; Mertes, T.; Ignatius, R. Antimicrobial resistance of Neisseria gonorrhoeae isolates in south-west Germany, 2004 to 2015: Increasing minimal inhibitory concentrations of tetracycline, but no resistance to third-generation cephalosporins. Eurosurveillance 2016, 21. [Google Scholar] [CrossRef] [PubMed]
- Brunner, A.; Nemes-Nikodem, E.; Jeney, C.; Szabo, D.; Marschalko, M.; Karpati, S.; Ostorhazi, E. Emerging azithromycin resistance among the Neisseria gonorrhoeae strains isolated in Hungary. Ann. Clin. Microbiol. Antimicrob. 2016, 15. [Google Scholar] [CrossRef] [PubMed]
- Yasuda, M.; Hatazaki, K.; Ito, S.; Kitanohara, M.; Yoh, M.; Kojima, M.; Narita, H.; Kido, A.; Miyata, K.; Dequch, T. Antimicrobial susceptibility of Neisseria gonorrhoeae in Japan from 2000 to 2015. Sex. Transm. Dis. 2017, 44, 149–153. [Google Scholar] [PubMed]
- World Health Organization. Antibiotic resistance gonorrhoea on the rise, new drugs needed. Available online: http://www.who.int/mediacentre/news/releases/2017/Antibiotic-resistant-gonorrhoea/en/ (accessed on 30 June 2017).
- Antibiotic Resistance Surveillance Program; Data Summary Report; Research Institute for Tropical Medicine: Muntinlupa, Philippines, 2016.
- Juayang, A.; Lim, J.P.; Acosido, M.A.; Maestral, D., Jr.; Gallega, C. Antibiotic susceptibility of Neisseria gonorrhoeae in Bacolod City, Philippines. BMRJ 2015, 10. [Google Scholar] [CrossRef]
- Ali, S.; Sewunet, T.; Sahlemariam, Z.; Kibru, G. Neisseria gonorrhoeae among suspects of sexually transmitted infection in Gambella Hospital, Ethiopia: Risk factors and drug resistance. BMC Res. Notes 2016, 9. [Google Scholar] [CrossRef] [PubMed]
- Toliman, P.; Lupiwa, T.; Law, G.; Reeder, J.; Siba, P. Neisseria gonorrhoeae isolates from four centres in Papua New Guinea remain susceptible to amoxycillin-clavulanate therapy. P. N. G. Med. J. 2010, 53, 15–20. [Google Scholar] [PubMed]
- Hsueh, P.R.; Tseng, S.P.; Teng, L.J.; Ho, S.W. High prevalence of ciprofloxacin resistant Neisseria gonorrhoeae in Northern Taiwan. Clin. Infect. Dis. 2005, 40, 188–192. [Google Scholar] [CrossRef] [PubMed]
- Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 26th ed.; Clinical Laboratory Standards Institute: Wayne, PA, USA, 2016; Volume M100S. [Google Scholar]
- Centers for Disease Control and Prevention. Neisseria gonorrhoeae reference strains for antimicrobial susceptibility testing. Available online: https://www.cdc.gov/std/gonorrhea/arg/b88-feb-2005.pdf (accessed on 28 June 2017).
- Department of Health. Millenials. na HIV Positive Dumami. (Millenials that are HIV positive are increasing in numbers). Available online: http://www.doh.gov.ph/sites/default/files/news_clips/062617-0002.pdf (accessed on 28 June 2017).
- Golparian, D.B.T. First antimicrobial resistance data and genetic characteristics of Neisseria gonorrhoeae isolates from Estonia, 2009–2013. New Microbes New Infect. 2014, 2, 150–153. [Google Scholar] [CrossRef] [PubMed]
- Centers for Disease Control and Prevention. Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: Oral cephalosporins no longer recommended treatment for gonococcal infections. Morb. Mortal. Wkly. Rep. (MMWR) 2012, 61, 590–594. [Google Scholar]
- Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines, 2015. Morb. Mortal. Wkly. Rep. (MMWR) 2015, 64, 60–68. [Google Scholar]
- Kovari, H.; de Melo, O.; Hauser, M.; Lauchli, S.; Meyer, J.; Weber, R.; Zbinden, R. Decreased susceptibility of Neisseria gonorrhoeae isolates from Switzerland to cefixime and ceftriaxone: Antimicrobial susceptibility data from 1990 and 2000 to 2012. BMC Infect. Dis. 2013, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cole, M.; Spiteri, G.; Town, K.; Unemo, M.; Hoffmann, S.; Chisholm, S.; Amato-Gauci, A.; van de Laar, M.; Ison, C. Risk factors for antimicrobial-resistant Neisseria gonorrhoeae in Europe. Sex. Transm. Dis. 2014, 41, 723–729. [Google Scholar] [CrossRef] [PubMed]
- Lo, J.Y.C.; Man Ho, K.; Chun, T.; Lo, A. Surveillance of gonococcal antimicrobial susceptibility resulting in early detection of emerging resistance. J. Antimicrob. Chemother. 2012, 67, 1422–1426. [Google Scholar] [CrossRef] [PubMed]
- Clendennen, T.E.; Hames, C.S.; Kees, E.S.; Price, C.; Rueppel, W.J.; Andrada, A.B.; Espinosa, G.E.; Kabrerra, G.; Wignall, F.S. In vitro antibiotic susceptibilities of Neisseria gonorrhoeae isolates in the Philippines. Antimicrob. Agents Chemother. 1992, 36, 277–282. [Google Scholar] [CrossRef] [PubMed]
- de los Reyes, M.R.; Pato-Mesola, V.; Klausner, J.; Manalastas, R.; Wi, T.; Tuazon, C.; Dallabetta, G.; Whittington, W.; Holmes, K. A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in The Philippines. Clin. Infect. Dis. 2001, 32, 1313–1318. [Google Scholar] [CrossRef] [PubMed]
- Gil-Setas, A.; Navascues-Ortega, A.; Beristain, X. Spectinomycin in the treatment of gonorrhoea. Euro Surveill. 2010, 15. [Google Scholar]
- Lee Ventola, C. The antibiotic resistance crisis. Part 1: Causes and threats. Pharm. Ther. 2015, 40, 277–283. [Google Scholar]
Age Group (Years) | Frequency |
---|---|
10–14 | 2 (2.27%) |
15–19 | 8 (9.09%) |
20–24 | 30 (34.09%) |
25–29 | 15 (17.05%) |
30–34 | 13 (14.77%) |
35–39 | 5 (5.68%) |
40–44 | 4 (4.55%) |
45–49 | 0 (0%) |
50–54 | 2 (2.27%) |
55–59 | 2 (2.27%) |
≥60 | 7 (7.95%) |
Antibiotics | No. of Isolates Tested | Susceptible | Non-Susceptible | Intermediate | Resistant |
---|---|---|---|---|---|
Ceftriaxone | 88 | 100% (88/88) | 0% (0/88) | - | - |
Cefixime | 86 | 82.6% (71/86) | 17.4% (15/86) | - | - |
Spectinomycin | 86 | 91.8% (79/86) | - | 1.2% (1/86) | 7.0% (6/86) |
Tetracycline | 78 | 5.1% (4/78) | - | 20.5% (16/78) | 74.4% (58/78) |
Ciprofloxacin | 82 | 4.9% (4/78) | - | 17.1% (14/82) | 78% (64/82) |
Penicillin G | 88 | 0% (0/88) | - | 0% (0/88) | 100% (88/88) |
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Araneta, C.M.P.; Juayang, A.C.; Lim, J.P.T.; Quilop, E.M.G.; Casaysay, N.J.G.; Tamesis, G.M.L.; Yude, T.M.G.; Romero, S.J.E.; Gayoba, R.C. Antibiotic Susceptibility Monitoring of Neisseria gonorrhoeae in Bacolod City, Philippines. Trop. Med. Infect. Dis. 2017, 2, 45. https://doi.org/10.3390/tropicalmed2030045
Araneta CMP, Juayang AC, Lim JPT, Quilop EMG, Casaysay NJG, Tamesis GML, Yude TMG, Romero SJE, Gayoba RC. Antibiotic Susceptibility Monitoring of Neisseria gonorrhoeae in Bacolod City, Philippines. Tropical Medicine and Infectious Disease. 2017; 2(3):45. https://doi.org/10.3390/tropicalmed2030045
Chicago/Turabian StyleAraneta, Clark Martin P., Alain C. Juayang, Joseph Peter T. Lim, Eleeza Marie G. Quilop, Nadine Joy G. Casaysay, Gene Marie L. Tamesis, Tricia Marie G. Yude, Sarah Joyce E. Romero, and Raziel C. Gayoba. 2017. "Antibiotic Susceptibility Monitoring of Neisseria gonorrhoeae in Bacolod City, Philippines" Tropical Medicine and Infectious Disease 2, no. 3: 45. https://doi.org/10.3390/tropicalmed2030045
APA StyleAraneta, C. M. P., Juayang, A. C., Lim, J. P. T., Quilop, E. M. G., Casaysay, N. J. G., Tamesis, G. M. L., Yude, T. M. G., Romero, S. J. E., & Gayoba, R. C. (2017). Antibiotic Susceptibility Monitoring of Neisseria gonorrhoeae in Bacolod City, Philippines. Tropical Medicine and Infectious Disease, 2(3), 45. https://doi.org/10.3390/tropicalmed2030045